Resumen
There is not a single pharmacological agent with demonstrated therapeutic efficacy for traumatic brain injury (TBI). With recent legalization efforts and the growing popularity of medical cannabis, patients with TBI will inevitably consider medical cannabis as a treatment option. Pre-clinical TBI research suggests that cannabinoids have neuroprotective and psychotherapeutic properties. In contrast, recreational cannabis use has consistently shown to have detrimental effects. Our review identified a paucity of high-quality studies examining the beneficial and adverse effects of medical cannabis on TBI, with only a single phase III randomized control trial. However, observational studies demonstrate that TBI patients are using medical and recreational cannabis to treat their symptoms, highlighting inconsistencies between public policy, perception of potential efficacy, and the dearth of empirical evidence. We conclude that randomized controlled trials and prospective studies with appropriate control groups are necessary to fully understand the efficacy and potential adverse effects of medical cannabis for TBI.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 1904-1917 |
Número de páginas | 14 |
Publicación | Journal of Neurotrauma |
Volumen | 38 |
N.º | 14 |
DOI | |
Estado | Published - jul. 15 2021 |
Publicado de forma externa | Sí |
Nota bibliográfica
Funding Information:This research was supported by grants from the National Institutes of Health (NIH; https://www.nih.gov; grant numbers NIH 01 R01 NS098494-01A1 and -03S1A1) to Andrew R. Mayer.
Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
ASJC Scopus Subject Areas
- Clinical Neurology
PubMed: MeSH publication types
- Journal Article
- Review